Search

You searched for "Glasgow"

73 results found

Rotterdam Prostate Cancer Risk app

1 July 2014 | | Urologic Oncology, Technological Developments
The widespread use of prostate specific antigen (PSA) testing has led to diagnostic difficulties for patients and urologists. The sensitivity and specificity characteristics of PSA are far from optimal. To try and improve the predictive accuracy of PSA measurements, nomograms...

Prostate cancer

8 November 2021 | | Urologic Oncology
Case 1 A 65-year-old man is referred to your two-week wait (2WW) clinic with a PSA of 7.0ng/mL. He has no lower urinary tract symptoms (LUTS), no past medical history, no family history of prostate cancer (PCa) and his performance...

Biomarkers in prostate cancer detection

1 July 2018 | | Basic Science Research, Technological Developments, Urologic Oncology
Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...

In conversation with Roger Kirby

3 September 2020
We were delighted to catch up with Roger Kirby, new President of the RSM, about his illustrious career in urology. Can you tell us a little bit about what led you into the field of urology and what have been...

Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction

3 September 2021 | | Urologic Oncology
Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...

The doctor as the patient: receiving bad news

13 March 2023 | Urologic Oncology
This article, written by a GP working in the NHS, gives a unique insight into the experience of being a urology patient and some thoughtful advice on ‘breaking bad news’. Day 1 Alarm bells ring. It’s spotting an email from...

History of prostate biopsy – part 2

1 September 2018 | | Basic Science Research, Technological Developments, Urologic Oncology
For Part 1 of this topic is available here. The major limitations of the transrectal ultrasound (TRUS) guided prostate biopsy (PBx) protocols are the risk of profound sepsis and the risk of persistently significant false negative rates, related to the...

Read all about it Sep/Oct 2016

1 September 2016 | Andrology, Basic Science Research, Endourology and Stones, Functional Urology, Infection, Neurourology, Paediatric Urology, Reconstructive Urology, Technological Developments, Trauma and Emergency Urology, Urologic Oncology, Uroradiology
It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a `cutting-edge’ new treatment / test and you don’t know what they are talking about! So this section...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

1 January 2016 | | Urologic Oncology, Technological Developments
The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...

The role of transperineal template biopsies in the diagnosis of prostate cancer

1 March 2014 | | Urologic Oncology
The case In 2002, Mr A, a 64-year-old software engineer, was referred by his GP for further investigation of a raised prostate specific antigen (PSA) of 6.2. His prostate felt benign. He underwent transrectal ultrasound guided (TRUS) prostate biopsies. This...

Uroscopy

1 September 2017 | Technological Developments
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). You may feel somewhat distanced from the medical practitioners of mediaeval Florence but...

The role of PET-CT imaging in prostate cancer

4 October 2021 | | Urologic Oncology
Prostate cancer (PCa) is the second most common cancer in the UK, with 43,000 cases in 2017-18 [1,2]. Accurate primary staging and the detection of suspected recurrence following treatment is vital for directing management and predicting prognosis. This has conventionally...